Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.15
OCR's Cash to Debt is ranked lower than
62% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. OCR: 0.15 )
OCR' s 10-Year Cash to Debt Range
Min: 0.05   Max: 67.66
Current: 0.15

0.05
67.66
Equity to Asset 0.41
OCR's Equity to Asset is ranked lower than
52% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 0.43 vs. OCR: 0.41 )
OCR' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.88
Current: 0.41

0.31
0.88
F-Score: 6
Z-Score: 3.29
M-Score: -2.92
WACC vs ROIC
5.72%
6.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.86
OCR's Operating margin (%) is ranked lower than
52% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 7.48 vs. OCR: 6.86 )
OCR' s 10-Year Operating margin (%) Range
Min: 3.14   Max: 11.55
Current: 6.86

3.14
11.55
Net-margin (%) 2.43
OCR's Net-margin (%) is ranked lower than
58% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 3.35 vs. OCR: 2.43 )
OCR' s 10-Year Net-margin (%) Range
Min: -1.76   Max: 6.75
Current: 2.43

-1.76
6.75
ROE (%) 6.04
OCR's ROE (%) is ranked lower than
60% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 9.41 vs. OCR: 6.04 )
OCR' s 10-Year ROE (%) Range
Min: -2.76   Max: 13.17
Current: 6.04

-2.76
13.17
ROA (%) 2.48
OCR's ROA (%) is ranked lower than
55% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 3.44 vs. OCR: 2.48 )
OCR' s 10-Year ROA (%) Range
Min: -1.44   Max: 6.68
Current: 2.48

-1.44
6.68
ROC (Joel Greenblatt) (%) 34.93
OCR's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 207 Companies
in the Global Medical Care industry.

( Industry Median: 14.26 vs. OCR: 34.93 )
OCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 11.67   Max: 65.94
Current: 34.93

11.67
65.94
Revenue Growth (3Y)(%) 3.90
OCR's Revenue Growth (3Y)(%) is ranked lower than
66% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. OCR: 3.90 )
OCR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.4   Max: 34
Current: 3.9

-0.4
34
EBITDA Growth (3Y)(%) 2.20
OCR's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 115 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. OCR: 2.20 )
OCR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -8.8   Max: 22.3
Current: 2.2

-8.8
22.3
EPS Growth (3Y)(%) 7.30
OCR's EPS Growth (3Y)(%) is ranked lower than
56% of the 111 Companies
in the Global Medical Care industry.

( Industry Median: 9.50 vs. OCR: 7.30 )
OCR' s 10-Year EPS Growth (3Y)(%) Range
Min: -49.6   Max: 86.6
Current: 7.3

-49.6
86.6
» OCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

OCR Guru Trades in Q2 2014

Joel Greenblatt 48,646 sh (+1336.68%)
Pioneer Investments 689,748 sh (+33.81%)
James Barrow 4,996,755 sh (+4.09%)
First Eagle Investment 844,500 sh (-0.21%)
Chuck Royce 56,599 sh (-5.67%)
Jim Simons 454,900 sh (-5.68%)
Paul Tudor Jones 100,564 sh (-56.72%)
» More
Q3 2014

OCR Guru Trades in Q3 2014

Ray Dalio 5,634 sh (New)
Joel Greenblatt 501,043 sh (+929.98%)
Jim Simons 1,125,800 sh (+147.48%)
James Barrow 5,059,633 sh (+1.26%)
First Eagle Investment 844,500 sh (unchged)
Pioneer Investments 705,443 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 52,399 sh (-7.42%)
» More
Q4 2014

OCR Guru Trades in Q4 2014

Louis Moore Bacon 165,000 sh (New)
Jim Simons 1,531,600 sh (+36.05%)
First Eagle Investment 844,500 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Chuck Royce 51,199 sh (-2.29%)
James Barrow 4,807,769 sh (-4.98%)
Pioneer Investments 636,307 sh (-9.80%)
» More
Q1 2015

OCR Guru Trades in Q1 2015

Joel Greenblatt 337,773 sh (New)
First Eagle Investment 844,500 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
James Barrow 4,801,304 sh (-0.13%)
Pioneer Investments 629,794 sh (-1.02%)
Jim Simons 698,100 sh (-54.42%)
» More
» Details

Insider Trades

Latest Guru Trades with OCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Omnicare Inc

Steven Romick Comments on Omnicare - Jul 29, 2013

Ultimately, we pay more attention to the underlying financial performance of the companies in our investment portfolio than we do their stock charts and in one instance, Omnicare (OCR), the largest supplier of pharmaceuticals to patients in nursing homes, delivered in spades. New management came in several years ago and began executing on a business plan that revolved around basic blocking and tackling to improve performance. While the engineer of the turnaround, John Figueroa, has handed off the plan to his successor, the momentum remained intact under the present CEO, John Workman. The company has lowered costs, reduced customer churn, won new accounts and essentially built the best mousetrap in the institutional pharmacy space. The net result is that all of the aforementioned improvements in aggregate have manifested themselves in the form of higher and more consistent earnings. Those achievements and the belief that the company's future continues to look bright are reflected in a stock price that has more than doubled from our original cost.

From Steven Romick's FPA Crescent Fund second quarter commentary.
Check out Steven Romick latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 63.40
OCR's P/E(ttm) is ranked lower than
104% of the 137 Companies
in the Global Medical Care industry.

( Industry Median: 23.60 vs. OCR: 63.40 )
Ranked among companies with meaningful P/E(ttm) only.
OCR' s 10-Year P/E(ttm) Range
Min: 10.93   Max: 122.41
Current: 63.4

10.93
122.41
Forward P/E 20.62
OCR's Forward P/E is ranked lower than
64% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 17.61 vs. OCR: 20.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.90
OCR's PE(NRI) is ranked lower than
77% of the 136 Companies
in the Global Medical Care industry.

( Industry Median: 26.40 vs. OCR: 50.90 )
Ranked among companies with meaningful PE(NRI) only.
OCR' s 10-Year PE(NRI) Range
Min: 9.68   Max: 639.6
Current: 50.9

9.68
639.6
P/B 3.90
OCR's P/B is ranked lower than
83% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 2.39 vs. OCR: 3.90 )
Ranked among companies with meaningful P/B only.
OCR' s 10-Year P/B Range
Min: 0.6   Max: 3.93
Current: 3.9

0.6
3.93
P/S 1.60
OCR's P/S is ranked lower than
68% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. OCR: 1.60 )
Ranked among companies with meaningful P/S only.
OCR' s 10-Year P/S Range
Min: 0.33   Max: 1.55
Current: 1.6

0.33
1.55
PFCF 17.20
OCR's PFCF is ranked lower than
60% of the 113 Companies
in the Global Medical Care industry.

( Industry Median: 15.38 vs. OCR: 17.20 )
Ranked among companies with meaningful PFCF only.
OCR' s 10-Year PFCF Range
Min: 4.79   Max: 71.06
Current: 17.2

4.79
71.06
POCF 15.43
OCR's POCF is ranked lower than
55% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 14.15 vs. OCR: 15.43 )
Ranked among companies with meaningful POCF only.
OCR' s 10-Year POCF Range
Min: 4.29   Max: 50.64
Current: 15.43

4.29
50.64
EV-to-EBIT 24.85
OCR's EV-to-EBIT is ranked lower than
61% of the 156 Companies
in the Global Medical Care industry.

( Industry Median: 19.07 vs. OCR: 24.85 )
Ranked among companies with meaningful EV-to-EBIT only.
OCR' s 10-Year EV-to-EBIT Range
Min: 8.7   Max: 30.5
Current: 24.85

8.7
30.5
PEG 15.42
OCR's PEG is ranked lower than
97% of the 67 Companies
in the Global Medical Care industry.

( Industry Median: 2.86 vs. OCR: 15.42 )
Ranked among companies with meaningful PEG only.
OCR' s 10-Year PEG Range
Min: 0.67   Max: 2547
Current: 15.42

0.67
2547
Shiller P/E 118.60
OCR's Shiller P/E is ranked lower than
142% of the 81 Companies
in the Global Medical Care industry.

( Industry Median: 25.00 vs. OCR: 118.60 )
Ranked among companies with meaningful Shiller P/E only.
OCR' s 10-Year Shiller P/E Range
Min: 9.31   Max: 118.67
Current: 118.6

9.31
118.67
Current Ratio 1.66
OCR's Current Ratio is ranked higher than
63% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 1.35 vs. OCR: 1.66 )
Ranked among companies with meaningful Current Ratio only.
OCR' s 10-Year Current Ratio Range
Min: 0.9   Max: 9.8
Current: 1.66

0.9
9.8
Quick Ratio 1.20
OCR's Quick Ratio is ranked higher than
50% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 1.20 vs. OCR: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
OCR' s 10-Year Quick Ratio Range
Min: 0.73   Max: 9.04
Current: 1.2

0.73
9.04
Days Inventory 33.35
OCR's Days Inventory is ranked lower than
69% of the 150 Companies
in the Global Medical Care industry.

( Industry Median: 17.87 vs. OCR: 33.35 )
Ranked among companies with meaningful Days Inventory only.
OCR' s 10-Year Days Inventory Range
Min: 30.61   Max: 39.1
Current: 33.35

30.61
39.1
Days Sales Outstanding 35.49
OCR's Days Sales Outstanding is ranked higher than
69% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 46.90 vs. OCR: 35.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCR' s 10-Year Days Sales Outstanding Range
Min: 32.92   Max: 98.27
Current: 35.49

32.92
98.27

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.90
OCR's Dividend Yield is ranked lower than
121% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. OCR: 0.90 )
Ranked among companies with meaningful Dividend Yield only.
OCR' s 10-Year Dividend Yield Range
Min: 0.15   Max: 1.32
Current: 0.9

0.15
1.32
Dividend Payout 0.45
OCR's Dividend Payout is ranked lower than
67% of the 100 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. OCR: 0.45 )
Ranked among companies with meaningful Dividend Payout only.
OCR' s 10-Year Dividend Payout Range
Min: 0.03   Max: 0.95
Current: 0.45

0.03
0.95
Dividend growth (3y) 75.00
OCR's Dividend growth (3y) is ranked higher than
97% of the 64 Companies
in the Global Medical Care industry.

( Industry Median: 12.60 vs. OCR: 75.00 )
Ranked among companies with meaningful Dividend growth (3y) only.
OCR' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 78
Current: 75

0
78
Yield on cost (5-Year) 10.58
OCR's Yield on cost (5-Year) is ranked higher than
93% of the 134 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. OCR: 10.58 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
OCR' s 10-Year Yield on cost (5-Year) Range
Min: 1.76   Max: 15.52
Current: 10.58

1.76
15.52
Share Buyback Rate 2.50
OCR's Share Buyback Rate is ranked higher than
91% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: -1.90 vs. OCR: 2.50 )
Ranked among companies with meaningful Share Buyback Rate only.
OCR' s 10-Year Share Buyback Rate Range
Min: 2.5   Max: -6.4
Current: 2.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
OCR's Price/DCF (Projected) is ranked lower than
73% of the 95 Companies
in the Global Medical Care industry.

( Industry Median: 1.20 vs. OCR: 1.60 )
Ranked among companies with meaningful Price/DCF (Projected) only.
OCR' s 10-Year Price/DCF (Projected) Range
Min: 0.39   Max: 7.87
Current: 1.6

0.39
7.87
Price/Median PS Value 2.30
OCR's Price/Median PS Value is ranked lower than
123% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. OCR: 2.30 )
Ranked among companies with meaningful Price/Median PS Value only.
OCR' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 6.75
Current: 2.3

0.52
6.75
Price/Peter Lynch Fair Value 6.70
OCR's Price/Peter Lynch Fair Value is ranked lower than
134% of the 56 Companies
in the Global Medical Care industry.

( Industry Median: 1.60 vs. OCR: 6.70 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
OCR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.48   Max: 7.07
Current: 6.7

0.48
7.07
Earnings Yield (Greenblatt) 4.00
OCR's Earnings Yield (Greenblatt) is ranked lower than
54% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 4.70 vs. OCR: 4.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
OCR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.3   Max: 11.5
Current: 4

3.3
11.5
Forward Rate of Return (Yacktman) 11.84
OCR's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 10.53 vs. OCR: 11.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
OCR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.2   Max: 24.3
Current: 11.84

3.2
24.3

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:OMN.Germany,
Omnicare Inc was formed in 1981 in Delaware. It is a healthcare services company that specializes in the management of complex pharmaceutical care. The Company operates two primary businesses, Long-Term Care Group and Specialty Care Group. Through Long-Term Care Group, the Company provides pharmaceuticals and related pharmacy services to long-term care facilities as well as chronic care facilities and other settings. Through Specialty Care Group, the Company provides specialty pharmacy and commercialization services for the biopharmaceutical industry. The Company's businesses engage in an ongoing program for the development and marketing of new services. The Company serves long-term care institutions and other chronic care settings in approximately 47 states in the U.S. and the District of Columbia. The Company's largest competitor nationally is PharMerica Corporation. It also competes with numerous local and regional institutional pharmacies, pharmacies owned by long-term care facilities and local retail pharmacies. The Company is subject to extensive federal, state and local regulation.
» More Articles for OCR

Headlines

Articles On GuruFocus.com
CVS Eyeing Omnicare Acquisition To Bolster Market Position May 23 2015 
CVS To Buy Out Omnicare For $10.4 Billion May 22 2015 
Glenview Capital Raises Stake In Monsanto May 21 2015 
phone Dec 18 2014 
It's Time to Follow Chris Davis and Buy Laboratory Corp Jan 15 2014 
Steven Romick’s Third Quarter Sells at FPA Crescent Fund Oct 17 2013 
Waiting for Gold Rain, Wally Weitz Does "Unnaturally Well" Sep 23 2013 
First Pacific Advisors’ Major Selling and Reductions in Second Quarter Aug 15 2013 
Steven Romick Comments on Omnicare Jul 29 2013 
Steven Romick on WealthTrack Oct 20 2012 

More From Other Websites
OMNICARE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout May 27 2015
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... May 27 2015
OMNICARE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... May 26 2015
CVS Deal for Omnicare Seen Avoiding PharMerica Antitrust Stumble May 26 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Omnicare Inc. of Commencement of an... May 26 2015
Ryan & Maniskas, LLP Announces Investigation of Omnicare Inc. May 26 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Omnicare, Inc.... May 22 2015
OMNICARE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... May 22 2015
CVS Health to Buy Omnicare for $12.7B; Eyes Specialty Care - Analyst Blog May 22 2015
Health-Care M&A Stays Hot with CVS-Omnicare Deal May 22 2015
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... May 22 2015
Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Omnicare, Inc. May 22 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Omnicare Inc. of Commencement of... May 22 2015
May 22 Premarket Briefing: 10 Things You Should Know May 22 2015
How Pricey Specialty Drugs Spurred CVS Health's Omnicare Deal May 22 2015
Five things you need to know today, and Cincinnati loses a Fortune 500 company May 22 2015
[$$] CVS Ages Gracefully With Omnicare Deal May 21 2015
As CVS Swoops Up Old Suitor, PharMerica’s Single and Loving It May 21 2015
CVS Health Buys Omnicare, Citing 'Long-Term' Benefits May 21 2015
Cramer: Snap judgments, stupid decisions May 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK